The Tirana Court has released Frigull Milla, (former) administrator of the pharmaceutical company "CFO Pharma", owned by Nadir Çausholli, from prison.
The decision was made on March 5, 2026, and Milla must now appear twice a month before Judicial Police officers.
Frigull Milla is suspected by the Tirana Prosecution Office as one of the key persons in a fraud scheme involving the reimbursement of medicines worth 700 thousand euros.
The Tirana Court imposed a security measure of "prison arrest" on him on November 4, 2025. However, Milla was not arrested by the Police for at least three weeks, until he surrendered on November 27 of last year.
Along with Milla, an arrest measure was also imposed on the former director of the Health Care Fund, Spartak Zekja, as well as more lenient measures for three employees of that institution and two subordinates of "CFO Pharma".
They are suspected of committing the criminal offenses of "Forgery of documents" and "Hiding income".
Investigation of the scheme
In the court file, consulted by "Boldnews.al", it appears that citizen Ilir Shehu is the administrator of the entity "Medicamenta", which is an exclusive pharmaceutical importer licensed and contracted with the Mandatory Health Insurance Fund, for the reimbursement of several medicines.
He alleges that he has become aware of the fact that the entity "CFO Pharma" and the entities "Pharma Plus" and "Medix Albania", in collaboration with public servants of the Health Insurance Fund, carry out fictitious sales and purchases of "Foster" and "Trimbow" products and, as a result of these fictitious actions (inventories), benefit from FSDKSH reimbursement funds in significant monetary amounts.
Given this fact, the injured party and its business partner, the Italian entity “Chiesi” Spa, held a meeting at the request of the complainant near the offices of FSDKSH, with representatives of this institution. The complainant had the opportunity to view in the statistics office and with the support of the Director of Control, some data, which were alarming to him. He found a scheme used to generate fictitious invoices, which cause theft of large amounts of reimbursement.
From the data published by the Fund on drug consumption, the data of the import and sales informant, but especially from the data they found in the statistics department at the Fund, they found an organized scheme with the aim of corruptly benefiting from reimbursement funds in very large amounts.
"CFO Pharma", at the center of the scheme
The report also states that at the center of this organized scheme is the pharmaceutical distributor "CFO Pharma" in collaboration with FSDKSH officials.
The distributors "Pharma Plus" (owned in letters by Alba Zylfo) and "Medix Albania" (owned in letters by Lorela Ballabani), are distributors established "de facto" by the owner of "CFO Pharma", who have signed a contract with FSDKSH on 04.10.2024 and 24.04.2025 respectively, where they have declared frightening, totally fictitious figures of the initial inventory status, with the aim of subsequent fictitious sales to "CFO Pharma" and then to pharmacies.
The entity “Pharma Plus” has declared 2,000 boxes of “Foster” and 1,107 boxes of “Trimbow” worth 10 million new lekë, without any purchase. The entity “Medix Albania” has declared 4,000 boxes of “Foster” and 11,500 boxes of “Trimbow”, worth 60 million new lekë, without any purchase.
The fact of the approval of these fictitious inventories and the conclusion of contracts with these entities by FSDKSH officials clearly indicates the involvement of Fund officials as part of this scheme. The fictitious sales of “Pharma Plus” and “Medix Albania” were made to “CFO Pharma” which issued fictitious invoices to several pharmacies.
What did the Prosecution discover?
The investigation clearly revealed that citizens Lorela Ballabani and Alba Zylfo "have no knowledge of how the entities "Nedix Albania" and "Pharma Plus" function and operate, respectively."
Both have not provided many explanations about the activities of the entities they administer, as they have stated that they were unaware of many important details of the investigation.
The entity "Pharma Plus" operates in the premises of "CFO Pharma", as well as in the warehouse, where a considerable amount of the supplement "Yovita Plus" was found during the inspection, part of which "CFO Pharma" transferred to "Pharma Plus" with a sales invoice, while the inspection of this entity's warehouse was being carried out.
So it is clear that this warehouse was used by "CFO Pharma" and not by the entity "Pharma Plus". A fact that is also proven by the medications left in the premises of this warehouse by "CFO Pharma", for which an undated agreement was made available to the investigation, which could have been drawn up even after the control exercised by the proceeding body.
These details, as well as other data, have led the Prosecution to believe that "Pharma Plus" was created and is used for the account and needs of the entity "CFO Pharma", as cited in the court file.
Likewise, the entity "Nedix Albania", from the analysis of its financial and commercial activity, results in the fact that it carried out all of its activity only with the entity "CFO Pharma", selling the latter medications for which it did not have a stock, falsifying purchase invoices, as well as the inventory status in the "edepo" system.
The address of the activity of the entity "Nedix Albania" is also a secondary address of the entity "CFO Pharma".
From the inspection carried out at Nedix Albania, only products of the entity "CFO Pharma" were found and not the medications that were in the inventory on 02.10.2025. This company had purchased the above warehouse only one day after "Nedix Albania" had signed the lease contract with the selling party.
According to the prosecution, this action was carried out with the direct intention of the administrator of the entity "CFO Pharma", to have the "Nedix Albania" warehouse under control.
Editorial
